Zanidatamab experience in advanced HER2-positive stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks at how patients with advanced HER2-positive stomach or gastroesophageal cancer feel and function while receiving zanidatamab as their first treatment. It aims to understand the real-world experiences and outcomes of this therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or gastroesophageal cancer that is HER2-positive (confirmed by a special test).
- Your doctor plans to start you on a treatment that includes zanidatamab as your first therapy for this cancer.
- You are 18 years or older.
- You are able to understand and answer questionnaires about your health and well-being.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new targeted drug called zanidatamab to standard chemotherapy before and after surgery can improve the chances of getting rid of HER2-positive stomach or esophageal cancer. It is designed for patients whose cancer can still be removed with surgery and has not spread.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
This trial tests whether a targeted drug (zanidatamab, which attacks HER2-positive cancer cells) combined with chemotherapy can shrink stomach cancer before surgery, making it easier to remove. It may also help people whose cancer has spread a bit, by making it operable.
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.